https://www.selleckchem.com/pr....oducts/trilaciclib.h
No thrombotic complications were reported under DOAC until last follow-up (14.1 ± 13 months). In comparison to 50 controls under VKA during the same period, the bleeding rate under DOAC was significantly lower (11.5 versus 22.9 per 100 patient-years, p=0.037) with a Hazard Ratio of 0.39 (95% CI, 0.19-0.85, p=0.041). No significant changes in kidney function, rejection rate or hemoglobin level were reported. CONCLUSIONS DOACs appear to be effective and safe anticoagulants in kidney transplant recipients with stable renal function.BAC
Like
Comment
Share
